Not for Dissemination within the US or via US Newswire Providers
TORONTO, Dec. 11, 2024 (GLOBE NEWSWIRE) — RAMM Pharma Corp. (together with its wholly owned subsidiaries, the Firm or “RAMM”) (CSE: RAMM), is offering an replace on its dispute with Sergio Martines and Naturale Science Inc. (plaintiffs), as beforehand reported in its press launch of Could twenty first 2024.
The Choose has dismissed the plaintiffs’ declare within the quantity of CAD 3,139,931.30 and has awarded Martines CAD 14,971.80 in unpaid bills. The Choose has additionally dismissed RAMM’s counterclaim within the quantity of CAD 14,220,000.
Causes for Judgement, printed on December ninth, 2024, could also be accessed on the Ontario Superior Courtroom of Justice web site.
About RAMM Pharma Corp.
RAMM Pharma is lively within the area of cannabinoid pharmacology and product formulation for cannabis-based prescription drugs and different hemp-based merchandise with a singular and diversified worldwide manufacturing and gross sales platform. The Firm operates a longtime pharmaceutical and medical product enterprise in Uruguay that has developed a number of medically registered and accepted plant-derived cannabinoid pharmaceutical merchandise which have been licensed on the market and/or compassionate use in a number of Latin American international locations. RAMM additionally has a pipeline of recent merchandise, together with registered hemp-based diet and specialised veterinary merchandise, in numerous phases of approval and improvement, that are produced on the firm’s state-of-the-art, good-manufacturing-practice-certified formulation facility in Montevideo, Uruguay.
In Europe, RAMM’s vertically built-in operations are based mostly in Ragusa, Italy and ElblÄ…g, Poland (60 kilometres east of GdaÅ„sk), and embody massive extraction and processing amenities (within the last phases of commissioning within the case of Canapar Corp.). RAMM Pharma consists of wholly owned subsidiaries Canapar Corp., HemPoland Sp. Z o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.
Further details about the Firm is on the market at www.wearerammpharma.com.
For additional info, please contact:
Josè Roldan
Interim CFO
+598 99 057 301
jroldan@rammpharma.com
Cautionary Word Relating to Ahead-Wanting Info
This information launch accommodates “forward-looking information” and “forward-looking statements” (collectively, “forward looking statements“) throughout the which means of the relevant Canadian securities laws. All statements, apart from statements of historic reality, are forward-looking statements and are based mostly on expectations, estimates and projections as on the date of this information launch. Any assertion that entails discussions with respect to predictions, expectations, beliefs, plans, projections, goals, assumptions, future occasions or efficiency (usually however not all the time utilizing phrases resembling expects, or doesn’t anticipate, is predicted, anticipates or doesn’t anticipate, plans, price range, scheduled, forecasts, estimates, believes or intends or variations of such phrases and phrases or stating that sure actions, occasions or outcomes might or may, would, would possibly or might be taken to happen or be achieved) should not statements of historic reality and could also be forward-looking statements. On this information launch, ahead wanting statements relate, amongst different issues, the Firm’s methods and goals, and future enlargement plans.
These forward-looking statements are based mostly on affordable assumptions and estimates of administration of the Firm on the time such statements have been made. Precise future outcomes might differ materially as forward-looking statements contain recognized and unknown dangers, uncertainties and different components which can trigger the precise outcomes, efficiency or achievements of the Firm to materially differ from any future outcomes, efficiency or achievements expressed or implied by such forward-looking statements. Such components, amongst different issues, embody: the decision of the litigation that Ramm is pursuing and defending; monetary threat in reference to the litigation; the quantity accrued within the Firm’s monetary statements in respect of the litigation; future progress potential of the Firm; fluctuations normally macroeconomic situations; fluctuations in securities markets; expectations relating to the dimensions of the Uruguayan, Latin American, European and worldwide medical and leisure hashish markets and altering client habits; the power of the Firm to efficiently obtain its enterprise goals; plans for enlargement; political and social uncertainties; incapacity to acquire ample insurance coverage to cowl dangers and hazards; and the presence of legal guidelines and rules which will impose restrictions on cultivation, manufacturing, distribution and sale of hashish and hashish associated merchandise in Uruguay or internationally; and worker relations. Though the forward-looking statements contained on this information launch are based mostly upon what administration of the Firm believes, or believed on the time, to be affordable assumptions, the Firm can’t guarantee shareholders that precise outcomes might be in step with such forward-looking statements, as there could also be different components that trigger outcomes to not be as anticipated, estimated or meant. Readers mustn’t place undue reliance on the forward-looking statements and data contained on this information launch. The Firm assumes no obligation to replace the forward-looking statements of beliefs, opinions, projections, or different components, ought to they alter, besides as required by regulation.
No inventory trade, securities fee or different regulatory authority has accepted or disapproved the knowledge contained herein.
Supply: RAMM Pharma Corp.
